News

The product, Staccato fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003

Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism

In addition, Alexza and Endo Pharmaceuticals have agreed to mutually terminate their development agreement for AZ-003 (Staccato fentanyl), a product development candidate that has completed Phase I clinical

Theragenetics, a personalised medicine diagnostics company which develops tests to improve the treatment of patients with central nervous system (“CNS”) disorders such as schizophrenia and depression.  Under the

According to the company, Zavesca is the first treatment to be approved for patients with Niemann-Pick type C disease, a very rare, invariably progressive and eventually fatal neurodegenerative

“We are very pleased to add Eric’s scientific expertise and leadership to our already strong senior management team,” said Carl Hull, Gen-Probe’s president and chief operating officer. “We

For the fourth quarter of 2008, Illumina reported revenue of $160.9 million, up 43% over the $112.6 million reported in the fourth quarter of 2007 and up 7%

The capital infusion will also serve to further the development of other innovative magnetic resonance image analysis technologies designed to increase physician productivity and accuracy, improve patient outcomes,

The funds will enable DNA Therapeutics to advance the vectorization and the additional proofs of concept, and to achieve regulatory preclinical studies of its lead product, named Dbait.